Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.

A Phase 3 trial investigating perifosine in combination with bortezomib (VELCADE®) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma is expected to commence by year-end under a Special Protocol Assessment (SPA) with the FDA. In addition, in September, the Company announced that perifosine had received Orphan-Drug designation in the United States for the treatment of multiple myeloma.

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "This Fast Track designation can significantly reduce the FDA review time of a new drug application, and therefore can expedite the time to market for perifosine in multiple myeloma." Mr. Bentsur added, "We believe that the Fast Track designation, together with the SPA and Orphan Drug status previously granted to us by the FDA for perifosine in multiple myeloma, significantly enhances the value proposition of perifosine in this indication. We are eager to begin the Phase 3 trial later this month."

KRX-0401 (perifosine) is in-licensed by
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... N.J., May 1, 2015 Cambrex Corporation (NYSE: ... 31, 2015. Highlights , Sales ... increased 27% excluding foreign currency impact, driven by Innovator products ... from $8.4 million in the first quarter of 2014. ... $0.04 in the first quarter last year and Adjusted Diluted ...
(Date:4/30/2015)... 2015 Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its first quarter ... for the first quarter of 2015 was $116.2 million, ... of 2014, and down $5.3 million or 4.4% from ... 2015 net income as reported in accordance with U.S. ...
(Date:4/30/2015)...  Thoratec Corporation (NASDAQ: THOR ), a world ... and restore failing hearts, said today it will participate ... Conference on Thursday, May 14. D. ... provide an update on the company, beginning at 10:40 ... The presentation will be available through the ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26
... for Perforomist(TM) (Formoterol Fumarate) Inhalation ... International ATS Conference --, NAPA, Calif., May ... of the American Thoracic Society (ATS) demonstrate,that concomitant ... FFIS), delivered by nebulization,and Spiriva(R) (tiotropium; TIO) is ...
... be Extended if Patients Receive the ... Most Effective Treatment Identified by ChemoFx, CHICAGO, May ... Assay, a cell-based test that examines the,response of a ... overall survival (OS) in patients with,primary ovarian cancer. Patients ...
Cached Medicine Technology:Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 2Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 3Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 4Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 5Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 6Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 2Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 3
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ Peachtree ... its monthly Tech Report, which features the latest and ... technology expert and special reporter for NewsWatch, conducted the ... high-end audio equipment. , Music is an important ... should be pampered and given the royal treatment. Peachtree ...
(Date:5/2/2015)... 2015 Kare Visits LLC. launched in Chicago ... caregivers. Kare Visits offers relief for caregivers by visiting ... According to the Caregiver Action Network, eight in ... 20 hours a week caring for an elderly or disabled ... hire a nurse, a caregiver is now empowered to schedule ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Frisco, Texas (PRWEB) May 02, 2015 ... Frisco, Texas, is proud to announce the addition of ... Jen Widerstrom is a life long athlete, growing up ... fitness passion after college by becoming a personal trainer ... since been the face of several TV shows highlighting ...
(Date:5/1/2015)... Farmington NY (PRWEB) May 01, 2015 ... world, will share the latest in their reclaimed wood ... (ICFF) at the Jacob Javits Center in NYC this ... Prairie Boards, will bring much anticipated texture and color ... “We've seen an explosion of texture and color in ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3
... death syndrome has been the cause of many infant deaths, ... on its back. In a bid to investigate the// latent ... born with an anomaly in three lungs related genes were ... study has undoubtedly made it easier to peg those infants ...
... nuclear scientist Abdul Qader Khan, diagnosed with prostate cancer, will ... informed of his health conditions, the// government has said. ... interest, the government would like to assure that best medical ... family and personal doctors, Dawn said in a report quoting ...
... top of many large commercial buildings hold a high number ... health, says a new study.// ,Sharon Berk and ... hospitals, universities and industries and 40 natural environments including lakes, ... of the cooling towers and only three in the natural ...
... incidence of self-harm in teenagers in England finds that it ... of more than 6,000 teenagers found that// self-harm is a ... of boys harmed themselves last year as compared to 11% ... They added that only 13 percent of the cases went ...
... had to bear a miscarriage at an emergency room in Calgary, ... emergency care.// The health quality council of Alberta is conducting the ... Lundy had filed a complaint after a shortage of beds in ... Rose to miscarry on July 18. The couple said the review ...
... Bradley Hasbro Children's Research Centre and Brown Medical School, earlier ... teenagers toward the use of condom with whom they perceive ... is vital for the development of an effective HIV intervention ... their study, as the concern in the current AIDS 2006 ...
Cached Medicine News:Health News:Pakistan Assures of Providing Best Medical Care to Abdul Qader Khan 2Health News:Usage Of A Condom By A Teenager Varies With Their Perception Of Partners 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: